Menu

Price Performance Heatmap

5Y Price (Market Cap Weighted)

All Stocks (12)

Company Market Cap Price
NVO Novo Nordisk A/S
At-home administration devices (auto-injector devices) for GLP-1 therapies are part of Novo Nordisk’s delivery platform.
$248.55B
$56.16
+1.91%
BDX Becton, Dickinson and Company
BD develops auto‑injector devices (wearable injectors) for home/at‑home administration of biologics.
$57.03B
$205.32
+3.20%
TAK Takeda Pharmaceutical Company Limited
ENTYVIO Pen demonstrates the use of auto-injector devices for at-home administration of biologics.
$49.74B
$15.80
+0.73%
WST West Pharmaceutical Services, Inc.
Auto-Injector Devices are a key product category in West's GLP-1 and other injectable platforms.
$20.06B
$281.49
+0.88%
ROIV Roivant Sciences Ltd.
Auto-injector devices enabling at-home administration for IMVT-1402, fitting Auto-Injector Devices.
$14.55B
$21.46
+0.77%
HALO Halozyme Therapeutics, Inc.
Halozyme is expanding its portfolio of auto-injector devices to enable at-home/self-administration of therapies.
$8.33B
$73.55
+3.29%
ATR AptarGroup, Inc.
Aptar has auto-injector devices/platforms for at-home administration of injectable therapies.
$8.10B
$121.42
-1.28%
STVN Stevanato Group S.p.A.
Develops and manufactures Auto-Injector Devices for at-home/self-administration of injectable therapies.
$6.37B
$21.79
+3.52%
AMRX Amneal Pharmaceuticals, Inc.
DHE autoinjector (Brekiya) approval signals involvement in auto-injector device delivery systems.
$3.99B
$13.02
+2.40%
KE Kimball Electronics, Inc.
Auto-injector devices represent a differentiated medical device assembly capability.
$690.71M
$29.89
+4.79%
SCPH scPharmaceuticals Inc.
Auto-Injector Devices reflect the SCP-111 autoinjector program for at-home administration.
$299.33M
$5.67
ASRT Assertio Holdings, Inc.
Otrexup is an auto-injector device, fitting the Auto-Injector Devices category.
$61.79M
$9.73
+1.09%

Loading company comparison...

Loading research report...

BDX Becton, Dickinson and Company

BD Reports First Phasix Mesh Prophylaxis Case in Greece, Advances PREVENT Trial Enrollment

Jan 05, 2026
HALO Halozyme Therapeutics, Inc.

Halozyme and Skye Bioscience Announce Collaboration to Develop Subcutaneous Nimacimab for Obesity

Jan 05, 2026
TAK Takeda Pharmaceutical Company Limited

Takeda and Protagonist File FDA NDA for Rusfertide, a First‑In‑Class Treatment for Polycythemia Vera

Jan 05, 2026
NVO Novo Nordisk A/S

Novo Nordisk Wins Supreme Court Patent Ruling in China, Securing Semaglutide Rights Ahead of 2026 Expiration

Dec 31, 2025
NVO Novo Nordisk A/S

Novo Nordisk Slashes Wegovy Prices in China to Counter Rising Generic Competition

Dec 29, 2025
NVO Novo Nordisk A/S

Novo Nordisk Receives FDA Approval for First Oral GLP‑1 Weight‑Loss Pill

Dec 23, 2025
ATR AptarGroup, Inc.

AptarGroup Announces Bidose System to Deliver FDA‑Approved CARDAMYST Nasal Spray for PSVT

Dec 18, 2025
HALO Halozyme Therapeutics, Inc.

FDA Approves RYBREVANT FASPRO, First Subcutaneous Targeted Therapy for EGFR‑Mutated Lung Cancer

Dec 18, 2025
TAK Takeda Pharmaceutical Company Limited

Takeda Reports Landmark Phase III Success for Oral Psoriasis Drug Zasocitinib

Dec 18, 2025
BDX Becton, Dickinson and Company

BD Adds Two IVDR‑Certified VIASURE Assays to BD MAX™ System Menu

Dec 16, 2025
NVO Novo Nordisk A/S

Novo Nordisk Launches Ozempic in India, Targeting a $24‑Per‑Week Price Point

Dec 13, 2025
NVO Novo Nordisk A/S

EMA Grants Positive Opinion for Novo Nordisk’s 7.2‑mg Wegovy, Expanding EU Obesity Portfolio

Dec 12, 2025